Journal article

Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma

Grace Kong, Michael S Hofman, William K Murray, Sharyn Wilson, Paul Wood, Peter Downie, Leanne Super, Annette Hogg, Peter Eu, Rodney J Hicks

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2016

Abstract

RATIONALE: Pediatric patients with refractory neuroblastoma have limited therapeutic options. Neuroblastoma may express somatostatin receptors (SSTRs) allowing imaging with 68Ga-DOTA-Octreotate (GaTATE) positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT). We reviewed our experience with this theranostic combination. MATERIALS AND METHODS: GaTATE studies (8 patients; 2 to 9 years old) were reviewed and compared with 123I-MIBG or posttreatment 131I-MIBG studies. Immunohistochemistry (IHC) for SSTR subtype 2 was performed in 5 patients. Four patients received PRRT. RESULTS: GaTATE PET showed additional disease in 38% (3/8 patients), and ups..

View full abstract

Grants

Funding Acknowledgements

The authors would like to thank the parents of these children for their support in agreeing to receive novel treatment options. Thank you to our pediatric nurses, Frances Ness and Jessy Thambiraj for coordinating scans and therapeutic interventions; to radiopharmacy and radiochemistry team of Peter Eu, Wayne Noonan, and Peter Roselt for their expertise; and to our nuclear medicine and PET technologists. R.J.H. has been the recipient of a Translational Research Grant from the Victorian Cancer Agency that partially funded the GaTATE PET/CT scans in these patients.